PFBT
BCRX icon

Parkside Financial Bank & Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01K Hold
201
– – ﹤0.01% 2183
2026
Q1 		$1.91K Buy
201
+53
+36% +$412 ﹤0.01% 2133
2025
Q4 		$1.16K Sell
148
-53
-26% -$383 ﹤0.01% 2295
2025
Q3 		$1.53K Buy
201
+14
+7% +$117 ﹤0.01% 2118
2025
Q2 		$1.68K Buy
187
+117
+167% +$1.09K ﹤0.01% 2061
2025
Q1 		$525 Buy
+70
New +$565 ﹤0.01% 2351

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Parkside Financial Bank & Trust's BCRX Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 201 shares worth $2.01K. The position accounts for ﹤0.01% of the portfolio, ranked #2183.

Parkside Financial Bank & Trust first reported a position in BCRX in Q1 2025 and has held it in 6 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Parkside Financial Bank & Trust held 201 shares of BioCryst Pharmaceuticals worth $2.01K as of Q2 2026.
  • Parkside Financial Bank & Trust left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2183 holding.
  • Parkside Financial Bank & Trust first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.